No Data
Do Its Financials Have Any Role To Play In Driving Hangzhou Tigermed Consulting Co., Ltd's (SZSE:300347) Stock Up Recently?
Southwest Securities: CXO industry revenues are recovering season by season, but the demand for preclinical services still needs to be restored.
From a short-term perspective, commercial orders continue to be digested, putting pressure on the apparent performance of CDMO; overseas mature CXO clinical pipelines are steadily advancing, and the preclinical demand still needs to be restored.
Trending Industry Today: PHARMARON Leads Losses In CRO Stocks
Hong Kong stocks fluctuate | CRO concept continues to decline, domestic biomedical investment and financing still at the bottom, overseas business development uncertainty increases.
CRO concept stocks continue to decline. As of the time of writing, wuxi apptec (02359) is down 6.13%, trading at 45.9 Hong Kong dollars; tigermed (03347) is down 5.88%, trading at 32 Hong Kong dollars; pharmaron (03759) is down 5.71%, trading at 13.2 Hong Kong dollars.
Hong Kong stock market review: Hang Seng Index fell by 0.53%, Hang Seng Tech Index fell by 1.24%, mainland real estate stocks showed a noticeable decline.
Most of the large technology stocks fell, with Kuaishou dropping 11.7% after earnings, marking the weakest performance.
Contract research organizations concept rises, Joinn Laboratories (06127) rises by 5.11%, institutions say CXO sector is expected to benefit from the recovery of overseas research and development demand.
Jinwu Financial News | The concept of contract research organizations has risen across the board, with joinn laboratories (06127) up 5.11%, tigermed (03347) up 4.33%, frontage (01521) up 2%, pharmaron (03759) up 1.84%, and wuxi bio (02269) up 0.79%. Zhongtai reported that the bank believes that as the medical insurance fund prepayment system continues to deepen and improve, and the supporting DRG/DIP system is continuously implemented in various provinces and cities, the long-term "triangle debt" relationship among hospitals, pharmaceutical companies, and medical insurance persists, and the "zero markup policy on pharmaceuticals" compresses hospital profitability.
No Data
